ReviewResults and problems in cell differentiation2026
Cellular and Molecular Aspects of Chronic Rejection.
Review in Results and problems in cell differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rejection is a principal cause of long-term graft failure in solid organ transplantation. Characterized by progressive fibrotic remodeling, chronic rejection results from complex interactions among alloimmune responses, persistent inflammation, and dysregulated tissue repair mechanisms. This chapter provides a comprehensive overview of the cellular and molecular mechanisms underlying chronic rejection, with a focus on the roles of innate immune cells, T and B lymphocytes, profibrotic cytokines, signaling pathways, and extracellular matrix remodeling. A detailed mechanistic understanding of these pathways is critical for the identification of novel biomarkers and the development of targeted therapeutic strategies to prevent or ameliorate chronic rejection, thereby improving long-term graft survival.
Indexed as
Identifiers
41479019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.